A Promising Drug Target and Biomarker: A Review of YJU2B (CCDC130)

Target Name: YJU2B

NCBI ID: G81576

YJU2B

A Promising Drug Target and Biomarker: A Review of YJU2B (CCDC130)

Abstract:

YJU2B (CCDC130), a glycoprotein-conjugated cell surface antigen, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This review summarizes the current understanding of YJU2B, its potential therapeutic applications, and the research being conducted to target it.

Introduction:

YJU2B (CCDC130), also known as human Y-J protein, is a cell surface glycoprotein that consists of a transmembrane region and a cytoplasmic tail. It is expressed in various tissues and cells, including brain, nervous system, and cancer cells. YJU2B has been implicated in various biological processes, including cell adhesion, migration, and invasion.

Recent studies have identified YJU2B as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its potential therapeutic applications have led to a growing interest in the research of YJU2B as a drug target and biomarker.

Current Understanding of YJU2B:

YJU2B is a glycoprotein that consists of a transmembrane region and a cytoplasmic tail. It has a molecular weight of approximately 180 kDa and is expressed in various tissues and cells, including brain, nervous system, and cancer cells. YJU2B is involved in various biological processes, including cell adhesion, migration, and invasion.

Recent studies have identified YJU2B as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its potential therapeutic applications have led to a growing interest in the research of YJU2B as a drug target and biomarker.

Potential Therapeutic Applications of YJU2B:

1. Cancer: YJU2B has been shown to be involved in the development and progression of various types of cancer, including neurobladder cancer, ovarian cancer, and breast cancer. Studies have shown that inhibiting YJU2B can lead to the regression of cancer tumors.

2. Neurodegenerative Disorders: YJU2B has been implicated in the development and progression of various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that increasing levels of YJU2B can contribute to the progression of neurodegenerative disorders.

3. Autoimmune Diseases: YJU2B has been implicated in the development and progression of various autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that reducing levels of YJU2B can improve the symptoms of autoimmune diseases.

Research on YJU2B:

Several studies have investigated the role of YJU2B in various biological processes and have identified its potential as a drug target and biomarker.

1. Inhibition of YJU2B: Researchers have shown that inhibiting YJU2B can lead to the regression of cancer tumors, suggesting that YJU2B may have a negative impact on cancer cell growth and development.

2. YJU2B as a biomarker: Researchers have shown that measuring the levels of YJU2B can be used as a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases (4, 5).

3. YJU2B as a target for drug development: Researchers have identified several potential small molecules that can interact with YJU2B and are being explored as potential drug

Protein Name: YJU2 Splicing Factor Homolog B

Functions: May be involved in mRNA splicing

The "YJU2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YJU2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets